Magdalena Kegel,  —

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

Articles by Magdalena Kegel

ALS Drug, Riluzole, Being Tested in Alzheimer’s Patients May Work by Protecting Neurons

Riluzole, a drug approved for the treatment of amyotrophic lateral sclerosis (ALS), might reverse genetic changes often observed in patients with Alzheimer’s disease and age-related cognitive decline. The findings support a clinical trial now exploring if riluzole is beneficial for Alzheimer’s patients. Researchers at Rockefeller University have previously shown that…

Failures in Alzheimer’s Vaccine Efforts Result of Research Errors, Scientist Says, And Suggests Ways of Correcting Them

All failed attempts to produce a viable vaccine against amyloid-beta in Alzheimer’s disease have one thing in common — they all used vaccine adjuvants that elicit the wrong kind of immune response, says Qantu Therapeutics’ president and CSO, Dante J. Marciani, in a sweeping retrospective analysis that covers errors in past and…

Alzheimer’s Disease Mechanism Traced to Genetic Defect That Lowers Levels of a Mitochrondrial Protein

Researchers at two Norwegian institutions found that deficits in the mitochondrial protein PITRM1 led to an accumulation of amyloid-beta, whose deposits in the brain are known to cause Alzheimer’s disease. The findings, drawn from a study of a family with a rare genetic defect, further suggest that mitochondria is a key player in neurodegenerative diseases.

Peptides with Neuroprotective Properties, Identified in Early Study, May Help Alzheimer’s Patients

A family of six mitochondrial small humanin-like peptides (SHLPs) showed promising effects on cell survival and metabolism in preclinical studies of aging, a finding with long-reaching implications for age-related conditions such as Alzheimer’s disease. The findings were announced by the biotechnology company CohBar, which holds the exclusive license for developing SHLPs…